The Why of Empagliflozin: Putting every diagnosed HF patient on SGLT2i [HF Experts’ Perspectives]

In this Why of Empagliflozin E-learning, Prof. Shelley Zieroth discusses the overview of Empagliflozin in heart failure in light of the guidelines recommendation, proven data, and its value in heart failure as it is recomended proven and convenient.
Prof. Zieroth also covered in the E-Learning the need to urgently recognize HFpEF as it is a highly unrecognized phenotype of heart failure, and discussion on diagnosing HFpEF.

For the portion of Prof. Robert Chilton, he shared on the value of Empagliflozin on the treatment of heart failure and chronic kidney disease, with or without T2D. Prof. Chilton also discussed about Empagliflozin’s ease of use and why this is very important for a patient with HF. Lastly, Prof. Chilton discussed the guidelines and information on the value of Empagliflozin specifically for Asian patients.

Estimated time of Completion: 32 mins

CPD Points: TBD